Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Ironwood Pharmaceuticals reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, and compared to a loss of $0.02 per share a year ago, indicating an earnings surprise of -180% [1] - The company posted revenues of $41.14 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 21.83%, and down from $74.88 million in the same quarter last year [2] - Over the last four quarters, Ironwood has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Ironwood shares have declined approximately 79.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The current Zacks Rank for Ironwood is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $64.03 million, and for the current fiscal year, it is $0.23 on revenues of $267.76 million [7] - The trend of estimate revisions for Ironwood is mixed, and changes in these estimates could impact stock performance [6] Industry Context - The Medical - Drugs industry, to which Ironwood belongs, is currently in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]